JOURNAL ARTICLE

Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor–patient communication in avoiding drug discontinuation.

  • Published In: British Journal of Dermatology, 2023, v. 188, n. 5. P. 586 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Valenti, Mario; Costanzo, Antonio 3 of 3

Abstract

Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation Of those receiving a systemic immune-modifying therapy, 619 (38.4%) were receiving a standard systemic therapy ( I n i = 121 as cotherapy) and 1113 (69.1%) were receiving a targeted therapy. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. [Extracted from the article]

Additional Information

  • Source:British Journal of Dermatology. 2023/05, Vol. 188, Issue 5, p586
  • Document Type:Article
  • Subject Area:Social Sciences and Humanities
  • Publication Date:2023
  • ISSN:0007-0963
  • DOI:10.1093/bjd/ljad014
  • Accession Number:163912442
  • Copyright Statement:Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.